Analysis on the World’s Schizophrenia Drugs Markets, 2016-2019 & 2026 –

DUBLIN–(BUSINESS WIRE)–The “Global Schizophrenia Drugs Market Analysis 2019” report has been added to’s offering.

The Schizophrenia Drugs market is expected to reach $10.16 billion by 2026 growing at a CAGR of 4.5% during 2018 to 2026.

Factors such as increased demand for enhanced therapy among patients, improvement in healthcare infrastructure, and rise in R&D expenditure in the field of medicine are driving the market growth. Though, social stigma of mental health conditions restrains the market growth. Moreover, rising healthcare expenditure is the opportunity for the schizophrenia drugs market.

Based on therapeutic class, the second-generation segment is going to have a lucrative growth during the forecast period, as it is the most commonly preferred medication. Also, it is FDA approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance treatment of the bipolar disorder and irritability associated with autistic disorders.

The key vendors mentioned are Eli Lilly, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Vanda Pharma, Otsuka Pharma, Alkermes, Sumitomo Dainippon, Allergan, AstraZeneca, Titan Pharmaceutical, Alexza Pharmaceuticals, Novartis, Yoshitomi Yakuhin Corporation, Braeburn Pharmaceuticals, and Merck & Co.

Key Questions Answered in this Report

  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analysed during the forecast period

Key Topics Covered

1 Market Synopsis

2 Research Outline

2.1 Research Snapshot

2.2 Research Methodology

2.3 Research Sources

2.3.1 Primary Research Sources

2.3.2 Secondary Research Sources

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Schizophrenia Drugs Market, By Type

5.1 Introduction

5.2 Catatonic Schizophrenia

5.3 Disorganized Schizophrenia

5.4 Paranoid Schizophrenia

5.5 Schizoaffective Disorder

6 Global Schizophrenia Drugs Market, By Therapeutic Class

6.1 Introduction

6.2 First-Generation

6.3 Second-Generation

6.4 Third-Generation

7 Global Schizophrenia Drugs Market, By Treatment Type

7.1 Introduction

7.2 Antipsychotics

7.3 Coordinated Specialty Care (CSC)

7.4 Psychosocial Treatments

7.5 Thioxanthenes

7.6 Oral

7.7 Injectables

8 Global Schizophrenia Drugs Market, By Application

8.1 Introduction

8.2 Unipolar Depression

8.3 Bipolar Disorder

8.4 Schizophrenia

8.5 Dementia

9 Global Schizophrenia Drugs Market, By End User

9.1 Introduction

9.2 Hospital Pharmacies

9.3 Clinics

9.4 Rehabilitation Centers

9.5 E-Commerce

9.6 Drug Stores/Retail Pharmacies

10 Global Schizophrenia Drugs Market, By Geography

10.1 North America

10.2 Europe

10.3 Asia-Pacific

10.4 South America

10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape

12.1 Eli Lilly

12.2 Johnson & Johnson

12.3 Pfizer

12.4 Bristol-Myers Squibb

12.5 Vanda Pharma

12.6 Otsuka Pharma

12.7 Alkermes

12.8 Sumitomo Dainippon

12.9 Allergan

12.10 AstraZeneca

12.11 Titan Pharmaceutical

12.12 Alexza Pharmaceuticals

12.13 Novartis

12.14 Yoshitomi Yakuhin Corporation

12.15 Braeburn Pharmaceuticals

12.16 Merck & Co.

For more information about this report visit


Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900